Table 3.
Activity as part of the injected dose per 89Zr-monocloncal antibody tracer 4 days post tracer injection.
| Tissue | VOI (%ID, ±SD) | |||
|---|---|---|---|---|
| 89Zr-lumretuzumab | 89Zr-MMOT0530A | 89Zr-bevacizumab | 89Zr-trastuzumab | |
| Total blood pool | 34.5 (± 8.4) | 33.5 (± 3.7) | 34.0 (± 5.7) | 30.9 (± 12.5) |
| Liver | 11.7 (± 2.3) | 14.2 (± 0.7) | 13.5 (± 2.4) | 10.3 (± 1.2) |
| Spleen | 1.8 (± 1.0) | 1.4 (± 0.5) | 0.9 (± 0.2) | 1.0 (± 0.1) |
| Kidney | 1.0 (± 0.4) | 1.1 (± 0.3) | 1.6 (± 0.9) | 1.1 (± 0.1) |
| Fat tissue | 7.4 (± 5.1) | 7.0 (± 2.2) | 5.4 (± 2.4) | 4.9 (± 2.7) |
| Tumor | 0.1 (± 0.1) | 0.4 (± 0.3) | 0.3 (± 0.2) | 0.9 (± 1.8) |
VOI, Volume of interest.